More than 400 comments were sent in regarding the American Society of Clinical Oncology (ASCO)'s Value Framework, and they will be incorporated as the framework evolves, explained Stephen Grubbs, MD, vice president for clinical affairs at ASCO.
More than 400 comments were sent in regarding the American Society of Clinical Oncology (ASCO)'s Value Framework, and they will be incorporated as the framework evolves, explained Stephen Grubbs, MD, vice president for clinical affairs at ASCO.
Transcript (slightly modified)
Are there plans to use feedback from the field to modify the ASCO Value Framework?
So the publication was done last year with the idea that people would comment upon that, and there’s been over 400 comments sent in to ASCO on this, and they are being taken into consideration and there are modifications of the tool. And beyond the comments, the tool needs to get more sophisticated in what it's measuring and I’ll give you an example.
Right now we’re measuring the net health benefit based on the advantage you get from the treatment but also the toxicities of the drugs. But we need to expand the negative part of that into how does it affect your family? How does it affect your quality of life? Can we get patient-reported outcomes involved in all this? So this is going to become very, very sophisticated, but at least the skeleton is there to build on right now.
This is not ready for primetime, but the conversation is going on, the modifications are being made, and we hope to see this evolve into an actually usable instrument where you might have a software program in your office where you can sit there with that patient. Of course, when you get to the cost part of it that’s different for every patient. It’s what payers are willing to pay for that and then what is their responsibility part of that so you have to adjust that per patient.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More